



**TO: Physicians, Hospitals**

**RE: Prior Authorization of Chimeric Antigen Receptor (CAR) – T Cell Therapy**

---

Effective July 1, 2022, the Department of Social Services (DSS) is removing prior authorization from chimeric antigen receptor CAR-T cell therapy. The following medical policies are being retired:

- Breyanzi<sup>®</sup> (lisocabtagene maraleucel)
- Kymriah<sup>®</sup> (tisagenlecleucel)
- Tecartus<sup>®</sup> (brexucabtagene autoleucel)
- Yescarta<sup>®</sup> (axicabtagene ciloleucel)

### **Elective Inpatient Admissions**

If CAR-T cell therapy will be administered on an inpatient basis, prior authorization is still required for the elective inpatient admission following the current process for requesting authorization for elective inpatient admissions through Community Health Network of Connecticut (CHNCT).

### **Prior Authorization Submission Process**

For questions regarding the prior authorization process, please contact CHNCT at 1-800-440-5071, between the hours of 8:00 a.m. and 6:00 p.m.